DiaMedica (TSX VENTURE:DMA) today announces that DM-199 has been validated by
demonstrating significantly increased insulin sensitivity in animals using the
hyperinsulemic euglycemic clamp model. Type 2 diabetes is a severely
debilitating condition characterized by high blood sugar primarily due to a
decrease in insulin sensitivity, which results in a number health problems
including cardiovascular disease. 


The amount of glucose being processed in an animal model of type 2 diabetes with
DM-199 was measured using the hyperinsulinemic euglycemic clamp, the gold
standard method for characterizing the actions of insulin. Animals treated with
a single dose of DM-199 had a 122% increase in maximal glucose infusion rate.
This enabled animals to process 77% more total glucose compared to untreated
animals. In a second study, DM-199 also had a pronounced anti-hypertensive
effect on systolic blood pressure. This is important as approximately 70% of
type 2 diabetes patients take multiple medications to treat high blood pressure.


"The clamp study clearly shows that treatment with DM-199 results in a major
increase in insulin sensitivity in an animal model of type 2 diabetes. It is
notable that the results of these studies actually provide an underestimate of
the true effectiveness of DM-199. This is because the potency of DM-199 was so
great that it was difficult to maintain the euglycemic clamp." stated Dr. David
Wasserman, Ron Santo Chair in Diabetes Research & Professor molecular physiology
and biophysics at Vanderbilt University. "I very much look forward to seeing the
future development of DM-199."


"The results from both studies provide further validation of DM-199, our next
generation form of DM-99, as a potential treatment for type 1 diabetes, type 2
diabetes and other diseases," said Mr. Rick Pauls, CEO of DiaMedica. "This
DM-199 data builds on compelling earlier animal and human proof of concept data
with DM-99, and gives us confidence in moving forward with this very promising
recombinant protein," continued Mr. Pauls. "The dual benefits shown by DM-199 to
increase the body's ability to metabolize glucose and its positive effect on
lowering systolic blood pressure may ultimately alleviate the need for diabetics
to take multiple drugs for diabetes and hypertension."


About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments
for type 1 diabetes, type 2 diabetes and other disorders. DiaMedica has
completed two successful proof-of-concept Phase II studies with DM-71 and DM-99,
which demonstrated human efficacy in lowering blood glucose levels in patients
with type 2 diabetes.


DiaMedica's lead product DM-199 is a novel recombinant next generation form of
DM-99, which has shown the potential to increase insulin sensitivity, reduce the
autoimmune attack and trigger proliferation of pancreatic beta cells, neural
stem cells and bone marrow cells. DiaMedica is listed on the TSX Venture
Exchange under the trading symbol "DMA". For further information please visit
www.diamedica.com.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, the "forward-looking statements"). These
forward-looking statements relate to, among other things, DiaMedica's
objectives, goals, targets, strategies, intentions, plans, beliefs, estimates
and outlook, and can, in some cases, be identified by the use of words such as
"believe," "anticipate," "expect," "intend," "plan," "will," "may" and other
similar expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release contains
forward-looking statements regarding matters such as, but not limited to, the
anticipated use of proceeds from the Offering, management's assessment of
DiaMedica's future plans, information with respect to the advancement of
DiaMedica's research and development programs, and DiaMedica's other estimates
and expectations. These statements reflect management's current beliefs and are
based on information currently available to management. Certain material factors
or assumptions are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in such
statements. Important factors that could cause actual results to differ
materially from these expectations include, among other things: uncertainties
and risks related to our research and development programs, the availability of
additional financing, risks and uncertainties relating to the anticipated use of
proceeds, changes in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change, uncertainties
related to forecasts, competition, potential product liability, additional
financing requirements and access to capital, unproven markets, the cost and
supply of raw materials, management of growth, effects of insurers' willingness
to pay for products, risks related to regulatory matters and risks related to
intellectual property matters.


Additional information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found in the body
of this news release, as well as under the heading "Risk Factors" contained in
DiaMedica's 2009 annual information form. DiaMedica cautions that the foregoing
list of important factors that may affect future results is not exhaustive. When
relying on DiaMedica's forward-looking statements to make decisions with respect
to DiaMedica, investors and others should carefully consider the foregoing
factors and other uncertainties and potential events. Such forward-looking
statements are based on a number of estimates and assumptions, which may prove
to be incorrect, including, but not limited to, assumptions regarding the
availability of additional financing for research and development companies, and
general business and economic conditions. These risks and uncertainties should
be considered carefully and investors and others should not place undue reliance
on the forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management believes to be
reasonable assumptions, DiaMedica cannot provide assurance that actual results
will be consistent with these forward-looking statements. DiaMedica undertakes
no obligation to update or revise any forward-looking statement.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more DiaMedica Inc. Charts.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more DiaMedica Inc. Charts.